ILMN Stock Recent News

Shares of Illumina (ILMN -8.97%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m.

Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.

Illumina's fourth-quarter revenues from the consumables business show robust growth.

Illumina, Inc. (NASDAQ:ILMN ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Conor McNamara - RBC Capital Markets Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies David Westenberg - Piper Sandler Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Patrick Donnelly - Citi Operator Good day, ladies and gentlemen and welcome to the Fourth Quarter 2024 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Illumina (ILMN) came out with quarterly earnings of $0.86 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.14 per share a year ago.

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling subdued demand for its genetic tests and diagnostic tools, sending shares down nearly 4% in extended trading.

Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on both a reported and constant currency basis Core Illumina GAAP operating margin of 15.8% and non-GAAP operating margin of 19.7% for Q4 2024; GAAP operating margin of 34.0% and non-GAAP operating margin of 21.3% for fiscal year 2024 Core Illumina GAAP diluted earnings per share (EPS) of $0.73 and non-GAAP diluted EPS of $0.95 for Q4 2024; GAAP diluted EPS of $5.61 and non-GAAP diluted EPS of $4.16 for fiscal year 2024 Core Illumina cash provided by operations of $1.2 billion and free cash flow of $1.1 billion for fiscal year 2024 Fiscal year 2025 guidance does not attempt to reflect any impact from the recent China Ministry of Commerce announcement and assumes a continuation of the current macroeconomic and political environments For fiscal year 2025, continue to expect Core Illumina constant

Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.

Genomic sequencing specialist Illumina (ILMN -5.26%) was something of a victim in the U.S.-China trade spat on Tuesday. The government of the sprawling Asian nation placed the U.S. company on a blacklist, and given the size and power of that economy, investors weren't happy about the news.